Gene therapy player bluebird bio has partnered with German biotech Medigene to develop and commercialize T cell receptor (TCR) immunotherapies against four…

Roche’s Genentech is pairing up with Hanmi Pharmaceutical to gain access to its Phase I pan-RAF inhibitor.

Amgen has handed over $56.5 million and committed to up to $617 million more to buy into Arrowhead’s efforts to aim RNAi therapies at cardiovascular targets.

In our EuroBiotech roundup this week, Noxxon lists in Paris, Summit's DMD drug boards the fast track, Bavarian Nordic poaches a CMO from the NCI and more.

Amgen and Novartis have cleared one of the final hurdles in the tight race to bring a CGRP migraine drug to market.

Acceleron has brought in a top commercial exec from Bayer, Habib Dable, to lead the company as it aims to plan for a marketed product.

Johnson & Johnson’s Janssen has licensed two early oncology assets to Tracon Pharmaceuticals through Phase I/II development, then the pharma has the…

Boehringer Ingelheim is making a bid in oncolytic viruses in a deal with preclinical ViraTherapeutics that’s worth up to €210 million. As part of the deal, the…